INMD Stock Overview
Designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 4/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
No risks detected for INMD from our risk checks.
My Notes
Capture your thoughts, links and company narrative
Community Narratives
Create a narrativeNarratives bring a range of perspectives from our community.
InMode Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.19 |
| 52 Week High | US$26.80 |
| 52 Week Low | US$14.87 |
| Beta | 2.11 |
| 1 Month Change | -2.94% |
| 3 Month Change | -1.32% |
| 1 Year Change | -24.41% |
| 3 Year Change | -76.15% |
| 5 Year Change | -9.72% |
| Change since IPO | 153.35% |
Recent News & Updates
InMode: Product Origination And Undervaluation Make The Stock A Buy
Dec 12InMode: $25/Share Is Closer Than You Think
Nov 05InMode Ltd. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 01
Recent updates
InMode: Product Origination And Undervaluation Make The Stock A Buy
Dec 12InMode: $25/Share Is Closer Than You Think
Nov 05InMode Ltd. Just Recorded A 17% EPS Beat: Here's What Analysts Are Forecasting Next
Nov 01InMode (NASDAQ:INMD) Could Be Struggling To Allocate Capital
Sep 24InMode Offers High Risk-Reward Opportunity Amid New Products And Rate Cuts (Rating Upgrade)
Sep 19InMode Stock: An Inverse Bubble Caused By Short-Term Trouble
Sep 06InMode: Still Undervalued, But Short-Term Risks Warrant Caution (Rating Downgrade)
Aug 12Here's What Analysts Are Forecasting For InMode Ltd. (NASDAQ:INMD) Following Its Earnings Miss
Aug 04InMode: Reversing Previous Shareholder Dilution With Buybacks
Jun 13Lacklustre Performance Is Driving InMode Ltd.'s (NASDAQ:INMD) Low P/E
May 29InMode: Facing A Myraid Of Headwinds
May 08InMode: More Headwinds Than Expected, Wait For A Floor To Materialize (Rating Downgrade)
Apr 27InMode's Quest For Growth Amidst Aesthetic Adversities
Apr 03InMode Does Not Look Pretty Right Now: Time To Buy
Mar 26InMode: Q4 Earnings Beat Not Enough - Macro Outlook Key To Buy Signal
Feb 16InMode: Take The Plunge Before It Goes Into Beast Mode
Feb 04Is InMode Ltd. (NASDAQ:INMD) Trading At A 49% Discount?
Jan 30InMode: Good Margin Of Safety At Current Levels
Jan 21Potential Upside For InMode Ltd. (NASDAQ:INMD) Not Without Risk
Dec 18InMode (NASDAQ:INMD) Will Want To Turn Around Its Return Trends
Oct 16If EPS Growth Is Important To You, InMode (NASDAQ:INMD) Presents An Opportunity
Jul 31InMode (NASDAQ:INMD) Knows How To Allocate Capital
Jul 16InMode Ltd. (NASDAQ:INMD) Shares Could Be 41% Below Their Intrinsic Value Estimate
May 22Capital Investment Trends At InMode (NASDAQ:INMD) Look Strong
Apr 05An Intrinsic Calculation For InMode Ltd. (NASDAQ:INMD) Suggests It's 33% Undervalued
Feb 20InMode (NASDAQ:INMD) Is Aiming To Keep Up Its Impressive Returns
Jan 03InMode (NASDAQ:INMD) Ticks All The Boxes When It Comes To Earnings Growth
Dec 01Is There An Opportunity With InMode Ltd.'s (NASDAQ:INMD) 48% Undervaluation?
Nov 12InMode gains after setting stronger-than-anticipated Q3 pre-results, guidance
Oct 13InMode: Recession May Kill Consumer Demand
Oct 05InMode: Aesthetic Tech Company Targeting Paradigm 2
Sep 13InMode Is On Its Launching Pad Again
Sep 02InMode (NASDAQ:INMD) Could Become A Multi-Bagger
Aug 23Is Now The Time To Put InMode (NASDAQ:INMD) On Your Watchlist?
Aug 05InMode: Alpha Long-Term Growth - Playing The Insurance Game Next
Aug 02InMode Set To Outperform Going Forward, We Join The Bull Camp
Jul 25InMode stock gains on guiding Q2 earnings above consensus; Raises FY2022 revenue outlook
Jul 12Shareholder Returns
| INMD | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | -7.1% | -3.4% | -3.5% |
| 1Y | -24.4% | 9.0% | 22.1% |
Return vs Industry: INMD underperformed the US Medical Equipment industry which returned 9% over the past year.
Return vs Market: INMD underperformed the US Market which returned 22.1% over the past year.
Price Volatility
| INMD volatility | |
|---|---|
| INMD Average Weekly Movement | 6.4% |
| Medical Equipment Industry Average Movement | 7.8% |
| Market Average Movement | 6.3% |
| 10% most volatile stocks in US Market | 17.0% |
| 10% least volatile stocks in US Market | 3.1% |
Stable Share Price: INMD has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: INMD's weekly volatility (6%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2008 | 581 | Moshe Mizrahy | www.inmodemd.com |
InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women’s health conditions and procedures. It also designs, develops, manufactures, and markets non-invasive medical aesthetic products that target an array of procedures, including permanent hair reduction, facial skin rejuvenation, wrinkle reduction, cellulite treatment, skin appearance and texture, and superficial benign vascular and pigmented lesions, as well as hands-free medical aesthetic products that target a range of procedures, such as skin tightening, fat reduction, and muscle stimulation.
InMode Ltd. Fundamentals Summary
| INMD fundamental statistics | |
|---|---|
| Market cap | US$1.45b |
| Earnings (TTM) | US$153.67m |
| Revenue (TTM) | US$423.75m |
9.5x
P/E Ratio3.4x
P/S RatioIs INMD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| INMD income statement (TTM) | |
|---|---|
| Revenue | US$423.75m |
| Cost of Revenue | US$77.80m |
| Gross Profit | US$345.95m |
| Other Expenses | US$192.28m |
| Earnings | US$153.67m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 1.82 |
| Gross Margin | 81.64% |
| Net Profit Margin | 36.26% |
| Debt/Equity Ratio | 0% |
How did INMD perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/19 05:50 |
| End of Day Share Price | 2024/12/19 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
InMode Ltd. is covered by 10 analysts. 7 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jeffrey Johnson | Baird |
| Matt Miksic | Barclays |
| Travis Steed | Barclays |